The significance of the hemoglobin A2 value in screening for hemoglobinopathies

Clinical Biochemistry

Volumn 42, Issue 18, 2009, Pages 1786-1796

  Giambona, Antonino ^a   Passarello, Cristina ^a   Renda, Disma ^a   Maggio, Aurelio ^a  

^a Azienda Ospedaliera Vincenzo Cervello   (Italy)

Author keywords

thalassemia; thalassemia; HbA2 borderline; Hemoglobin A2; Hemoglobinopathy screening

Indexed keywords

GLOBIN; HEMOGLOBIN A2;

BETA THALASSEMIA; CLINICAL FEATURE; DNA DETERMINATION; GENE EXPRESSION; GENE MUTATION; HEMOGLOBIN ANALYSIS; HEMOGLOBINOPATHY; HETEROZYGOTE DETECTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MICROCYTOSIS; NONHUMAN; PHENOTYPE; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVIEW;

GENETIC TESTING; HEMOGLOBIN A2; HEMOGLOBINOPATHIES; HETEROZYGOTE; HUMANS; PHENOTYPE;

EID: 70449713562     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2009.06.026     Document Type: Review

References (163)

1. Weatherall D.J., and Clegg J.B. Inherited haemoglobin disorders: an increasing global health problems. Bull. W. H. O. 79 (2001) 740-741
2. Weatherall D.J., and Clegg J.B. The thalassemia syndromes. 4th ed. (2001), Blackwell Science LTD, Publication, Oxford
3. Angastiniotis M., and Modell B. Global epidemiology of haemoglobin disorders. Ann. N. Y. Acad. Sci. 850 (1988) 251-269
4. Angastiniotis M. Epidemiology. Prevention of thalassemia and other haemoglobin disorders. Thalassaemia International Federation Publications 1 (2003) 10-23
5. Clegg J.B., and Weatherall D.J. Thalassemia and malaria: new insights into and an old problem. Proc. Assoc. Am. Physicians 111 (1999) 278-282
6. Roberts D.J., and Williams T.N. Haemoglobinopathies and resistance to malaria. Redox Rep. 8 (2003) 304-310
7. Flint J., Harding R.M., Boyce A.J., and Clegg J.B. The population genetics of the hemoglobinopaathies. Baillieres Clin. Haematolog. 11 (1998) 1-15
8. Flint J., Harding R.M., Clegg J.B., and Boyce A.J. Why are some genetic diseases common? Distinguishing selection from other processes by molecular analysis of globin gene variants. Hum Genet 91 (1993) 91-117
9. Labie D., Bennani C., and Beldjord C. β-thalassemia in Algeria. Ann. N. Y. Acad. Sci. 612 (1990) 43-54
10. Loukopoulos D., and Kollia P. Worldwide distribution of thalassemia. In: Steimberg M.H., Forget B., Higgs DR., and Nagel R.I. (Eds). Disorders of hemoglobin. Genetics, pathophysiology and clinical management (2001), Cambridge University Press 861-877
11. Fessas P. Prevention of thalassemia and haemoglobin S syndromes in Greece. Acta Haematol. 78 (1987) 68-72
12. Fattoum S. Hemoglobinopathies in Tunisia. An updated review of the epidemiologic and molecular data. Tunis Med. 84 (2006) 687-696
13. Ringelhann B., Szelenyi J.G., Horanyi M., et al. Molecular characterization of β-thalassemia in Hungary. Hum. Genet. 92 (1993) 385-387
14. Zdeska E., Krawcewicz A., Adamowicz-Salach A., et al. Beta-thalassemia in Poland. I. Mediterranean Mutations in beta-thalassemia. Pol. Merkuriusz. Lek. 20 (2006) 53-56
15. Knott M., Ramadan K.M., Savage G., et al. Novel and Mediterranean beta thalassemia mutations in the indigenous Northern Ireland population. Blood Cells Mol. Dis. 36 (2006) 265-268
16. Wildmann C., Larondelle Y., Vaerman J.L., Eeckels R., Martiat P., and Philippe M. An initiation codon mutation as a cause of β-thalassemia in a Belgian family. Hemoglobin 17 (1993) 19-30
17. Vichinsky E.P., MacKlin E.A., Waye J.S., Lorey F., and Olivieri N.F. Changes in epidemiology of the thalassemia in the North America: a new minority disease. Pediatrics 116 (2005) 818-825
18. Michlitsch J., Azimi M., Hoppe C., et al. Newborn screening for hemoglobinopathies in California. Pediatr. Blood Cancer 52 (2009) 486-490
19. Fucharoen S., and Winichagoon P. Hemoglobinopathies in Southeast Asia. Hemoglobin 11 (1987) 65-88
20. Wasi P. Geographic distribution of hemoglobin variants in Southern Asia. Winter in WP. Hemoglobin variants in human populations. Floridia: CRC Press Inc. 2 (1986) 111-127
21. Bianco I., Graziani B., Lerone M., et al. A screening programme for the prospective prevention of Mediterranean anaemia in Latium: results of seven years' work. J. Med. Genet. 21 (1984) 268-271
22. Maggio A., Di Marzo R., Giambona A., et al. Beta-thalassemia mutations in Sicily. Ann. N. Y. Acad. Sci. 612 (1990) 67-73
23. Toffoli C., Venturoli A., Bardi A., Lucci M., and Vullo C. Haplotypes of thalassaemic families from the Po river delta: importance for prenatal diagnosis of beta-thalassaemia. Eur. J. Haematol. 40 (1988) 410-414
24. Carestia C., Pagano L., Fioretti G., and Mastrobuoni A. Beta-thalassaemia in Campania: DNA polymorphism analysis in beta A and beta thal chromosomes and its usefulness in prenatal diagnosis. Br. J. Haematol. 67 (1987) 231-234
25. Cao A., Rosatelli M.C., and Galanello R. Control of beta-thalassaemia by carrier screening, genetic counselling and prenatal diagnosis: the Sardinian experience. Ciba Found. Symp. 197 (1996) 137-151
26. Cao A., Galanello R., and Rosatelli M.C. Genotype-phenotype correlations in beta-thalassemias. Blood Rev. 8 (1994) 1-12
27. Bianco I., Cappabianca M.P., Foglietta E., et al. Silent thalassemias: genotypes and phenotypes. Haematologica 82 (1997) 269-280
28. Giambona A., Lo Gioco P., Marino M., et al. The great heterogeneity of thalassemia molecular defects in Sicily. Hum. Genet. 95 (1995) 526-530
29. 2 determination. Vnitr. Lek. 41 (1995) 302-306
30. 2 testing in the diagnosis of thalassaemias and related haemoglobinopathies. J. Clin. Pathol. 62 (2009) 13-17
31. 2 levels: implication for beta-thalassemia carrier screening. Am. J. Hematol. 46 (1994) 79-81
32. Patrinos G.P., Kollia P., and Papadakis N. Molecular diagnosis of inherited disorders: lessons from hemoglobinopathies. Hum. Mut. 26 (2005) 399-412
33. Galanello R., and Cao A. Relationship between genotype and phenotype. Thalassemia intermedia. Ann. N. Y. Acad. Sci. 850 (1988) 325-333
34. Giordano P.C., Bakker-Verwij M., and Harteveld C.L. Frequency of alpha-globin gene triplications and their interaction with beta-thalassemia mutations. Hemoglobin 33 (2009) 124-131
35. Cao A. Carrier screening and genetic counselling in beta-thalassemia. Int. J. Hematol. 76 (2002) 105-113
36. Hattori Y. Thalassemia mutations and their clinical aspects in Japan. Int. J. Hematol. 76 (2002) 90-92
37. Stamatoyannopoulos G., and Grosveld F. In: Stamatoyannopoulos G., Majerus P.W., Perimutter R.M., and Varmus H. (Eds). The molecular basis of blood disease (2001), Saunders, New York 135-182
38. 2: origin, evolution and aftermath. Blood 78 (1991) 2165-2177
39. 2. Am. J. Hematol. 42 (1993) 107-111
40. Kunkel H.G., Ceppelini R., Muller-Eberhard U., and Wolf J. Observations of the minor basic hemoglobin component in the blood of normal individuals and patients with thalassemia. J. Clin. Invest. 36 (1957) 1615-1625
41. Wood W.G., Old J.M., Roberts A.V., Clegg J.B., and Weatherall D.J. Human globin gene expression: control of beta, delta and delta beta chain production. Cell 6 (1982) 437-446
42. Humphries R.K., Ley T., Turner P., Moulton A.D., and Nienhuis A.W. Differences in human alpha-, beta- and delta-globin gene expression in monkey kidney cells. Cell 30 (1982) 173-183
43. Antoniou M., and Grosveld F. Beta-globin dominant control region interacts differently with distal and proximal promoter elements. Genes Dev. 4 (1990) 1007-1013
44. Zertal-Zidani S., Ducrocq R., Weil-Olivier C., Elion J., and Krishnamoorthy R.A. novel delta beta fusion gene expresses hemoglobin A (HbA) not Hb Lepore: Senegalese delta(0)beta(+) thalassemia. Blood 98 (2001) 1261-1263
45. Baudin-Chich V., Rochette J., and Wajcman H. Strategy for structural characterization of haemoglobin variants. Acta Haematol. 78 (1987) 127-129
46. Kleinert P., Schmid M., Zurbriggen K., et al. Mass spectrometry: a tool for enhanced detection of hemoglobin variants. Clin. Chem. 54 (2008) 69-76
47. Clarke G., and Higgins T.N. Laboratory investigation of hemoglobinopathies and thalassemia: review and update. Clin. Chem. 46 (2000) 1284-1290
48. Old J.M. Screening and genetic diagnosis of haemoglobin disorders. Blood Rev. 17 (2003) 43-53
49. 2 testing in the diagnosis of thalassemias and related haemoglobinopathies. J. Clin. Pathol. 62 (2009) 13-17
50. Bain B.J. Hemoglobinopathy diagnosis (2001), Blackwell Science LTD, Oxford, England
51. Basset P., Beuzard Y., Garrel M.C., and Rosa J. Isoelectric focusing of human hemoglobin: its application to screening, to the characterization of 70 variants and to the study of modified fractions of normal hemoglobins. Blood 51 (1978) 971-982
52. International Committee for Standardization in Haematology. Recommendations for reference method for haemoglobinometry in human blood (ICSH standard EP 6/2: 1977) and specifications for international haemiglobin cyanide reference preparation (ICSH standard EP 6/3: 1977). J. Clin. Pathol. 31 (1978) 139-143
53. 2 on the DEAE-sephadex column. Atti. Accad. Fisiocrit. Siena, Med. Fis. 15 (1966) 63-66
54. 2. J. Lab. Clin. Med. 86 (1975) 700-702
55. 2 with DE-52 microchromatography in whole blood as screening test for beta thalassemia heterozygotes. Acta Haematol. 57 (1977) 32-36
56. 2) quantitation. Am. J. Clin. Pathol. 71 (1979) 388-396
57. 2 and F. Clin. Chem. 45 (1999) 237-243
58. 2 quantitation assay and hemoglobin variant screening by capillary electrophoresis. J. Capillary Electrophor. 4 (1997) 137-143
59. Jenkins M., and Ratnaike S. Capillary electrophoresis of hemoglobin. Clin. Chem. Lab. Med. 41 (2003) 747-754
60. Wang J., Zhou S., Huang W., et al. CE-based analysis of hemoglobin and its applications. Clin. Anal. Electrophor. 27 (2006) 3108-3124
61. 2 measured by the capillary system. Am J Clin Pathol 2009;131:42-8.
62. 2 quantification by capillary zone electrophoresis. Electrophoresis 21 (2000) 749-752
63. Hempe J.M., Granger J.N., and Craver R.D. Capillary isoelectric focusing of hemoglobin variants in the pediatric clinical laboratory. Electrophoresis 18 (1997) 1785-1795
64. Ishioka N., Iyori N., Noji J., and Kurioka S. Detection of abnormal haemoglobin by capillary electrophoresis and structural identification. Biomed. Chromatogr. 6 (1992) 224-226
65. Mario N., Baudin B., Aussel C., and Giboudeau J. Capillary isoelectric focusing and high-performance cation-exchange chromatography compared for qualitative and quantitative analysis of hemoglobin variants. Clin. Chem. 43 (1997) 2137-2142
66. Galanello R., Barella S., Gasperini D., et al. Evaluation of an automatic HPLC analyser for thalassemia and haemoglobin variants screening. J. Automat. Chem. 17 (1995) 73-76
67. Colah R.B., Surve R., Sawant P., et al. HPLC studies in hemoglobinopathies. Indian J. Pediatr. 74 (2007) 657-662
68. 2 by high-performance liquid chromatography. Am. J. Clin. Pathol. 123 (2005) 657-661
69. 2 and F. J. Clin. Pathol. 46 (1993) 852-856
70. Lafferty J.D., McFarlane A.G., and K Chui D.H. Evaluation of a dual hemoglobin A(2)/A(1c) quantitation kit on the bio-rad variant II automated hemoglobin analyzer. Arch. Pathol. Lab. Med. 126 (2002) 1494-1500
71. Campbell M., Henthorn J.S., and Davies S.C. Evaluation of cation-exchange HPLC compared with isoelectric focusing for neonatal hemoglobinopathy screening. Clin. Chem. 45 (1999) 969-975
72. 2 is higher in sickle cell trait than in normal homozygotes. Hemoglobin 5 (1981) 371-378
73. 2 quantification by HPLC. Clin. Chem. 42 (1996) 1113-1114
74. 2 in patients with AC trait, CC disease, and C-thalassemia. Clin. Chim. Acta 40 (1972) 159-163
75. Cotton F., Gulbis B., Hansen V., and Vertongen F. Interference of hemoglobin D in hemoglobin A(2) measurement by cation-exchange HPLC. Clin. Chem. 44 (1998) 2381-2382
76. Huisman T.H. Combinations of beta chain abnormal hemoglobins with each other or with beta-thalassemia determinants with known mutations: influence on phenotype. Clin. Chem. 44 (1998) 2381-2382
77. Sanchaisuriya K., Chunpanich S., Fucharoen G., and Fucharoen S. Multiplex allele-specific PCR assay for differential diagnosis of Hb S, Hb D-Punjab and Hb Tak. Clin. Chim. Acta 343 (2004) 129-134
78. Trent R.J.A. Diagnosis of the hemoglobinopathies. Clin. Biochem. 27 (2006) 27-38
79. Kutlar F. Diagnostic approach to hemoglobinopathies. Hemoglobin 31 (2007) 243-250
80. Working Party of the General Haematology Task Force of the British Committee for Standards in Haematology. Guideline: the laboratory diagnosis of haemoglobinopathies. Br. J. Haematol. 101 (1988) 783-792
81. Rosatelli C., Leoni G.B., Tuveri T., et al. Heterozygous β-thalassemia: relationship between the hematological phenotype and the type of β-thalassemia mutation. Am. J. Hematol. 39 (2006) 1-4
82. Old J.M. Screening and genetic diagnosis of haemoglobinopathies. Scand. J. Clin. Invest. 67 (2007) 71-86
83. 2 in patients with different beta-thalassemia mutations and a delta chain variant. Blood 76 (1990) 1246-1249
84. 2 in heterozygotes and homozygotes for beta-thalassemia mutations: influence of mutations in the CACCC and ATAAA motifs of the beta-globin gene promoter. Acta Haematol. 98 (1997) 187-194
85. Schiliro G., Musumeci S., Pizzarelli G., Fischer A., Romero M.A., and Russo G. Haemoglobin Lepore Boston-Washington in Sicily: clinical, haematological, and biosynthetic studies. J. Med. Genet. 17 (1980) 179-182
86. Efremov D.G., Efremov G.D., Zisovski N., et al. Variation in clinical severity among patients with Hb Lepore-Boston-β-thalassaemia is related to the type of β-thalassaemia. Br. J. Haematol. 68 (1988) 351-355
87. Baird M., Schreiner H., Driscoll C., and Bank A. Localization of the site of recombination in formation of the Lepore Boston globin gene. J. Clin. Invest. 68 (1981) 560-564
88. Ostertag W., and Smith E.W. Hemoglobin Lepore Baltimore,a third type of a δβ crossover (δ50/β86). Eur. J. Biochem. 10 (1969) 371-376
89. Barnabas J., and Muller C.J. Hemoglobin Lepore Hollandia. Nature 194 (1962) 931-932
90. Rees D.C., Styles L., Vichinsky E.P., Clegg J.B., and Weatherall D.J. The hemoglobin E syndromes. Ann. N. Y. Acad. Sci. 850 (1998) 334-343
91. Tachavanich K., Viprakasit V., Chinchang W., Glomglao W., Pung-Amritt P., and Tanphaichitr V.S. Clinical and hematological phenotype of homozygous hemoglobin E: revisit of a benign condition with hidden reproductive risk. Southeast Asian J. Trop. Med. Public Health 40 (2009) 306-316
92. Sanchaisuriya K., Fucharoen G., Sae-ung N., Jetsrisuparb A., and Fucharoen S. Molecular and hematologic features of hemoglobin E heterozygotes with different forms of alpha-thalassemia in Thailand. Ann. Hematol. 82 (2003) 612-616
93. Fucharoen S., and Winichagoon P. Clinical and hematologic aspects of hemoglobin E beta-thalassemia. Curr. Opin. Hematol. 7 (2000) 106-112
94. Nuntakarn L., Fucharoen S., Fucharoen G., Sanchaisuriya K., Jetsrisuparb A., and Wiangnon S. Molecular, hematological and clinical aspects of thalassemia major and thalassemia intermedia associated with Hb E-beta-thalassemia in Northeast Thailand. Blood Cells Mol. Dis. 42 (2009) 32-35
95. Wong S.C., Aw T.C., Suri R., Wong C.K., Plaseska D., and Efremov G.D. Differential diagnosis of Hb EE and Hb E-beta(0)-thalassemia by protein and DNA analyses. Acta Haematol. 103 (2000) 84-89
96. Markley K.M., Elkhalifa M., Maini A., and Hoyer J.D. Hb Jeddah [alpha68(E17)Asn-->His (alpha1)]: a newly recognized alpha chain variant, seen in combination with Hb S [beta6(A3)Glu-->Val], and found in three separate families of middle eastern origin. Hemoglobin 32 (2008) 297-302
97. Elion J., Belkhodja O., Wajcman H., and Labie D. Two variants of hemoglobin D in the Algerian population: hemoglobin D Ouled Rabah 19 (BI) Asn leads to Lys and hemoglobin D Iran 22 (Br) Glu leads to Gln. Biochim. Biophys. Acta 310 (1973) 360-364
98. Braconnier F., Gacon G., Thillet J., et al. Hemoglobin Fort de France (alpha2(45)(CD3) His replaced by Arg beta2). A new variant with increased oxygen affinity. Biochim. Biophys. Acta 493 1 (1977) 228-233
99. So C.C., Chan A.Y., Tsang S.T., et al. A novel beta-delta globin gene fusion, anti-Lepore Hong Kong, leads to overexpression of delta globin chain and a mild thalassaemia intermedia phenotype when co-inherited with beta(0)-thalassaemia. Br. J. Haematol. 136 (2007) 158-162
100. 2 beta thalassemia by direct sequencing of single strand enriched amplified genomic DNA. Blood 73 (1989) 924-930
101. Anand R., Boehm C.D., Kazazian Jr. H.H., and Vanin E.F. Molecular characterization of a beta zero-thalassemia resulting from a 1.4 kilobase deletion. Blood 72 (1988) 636-641
102. Gonzalez-Redondo J.M., Kattamis C., and Huisman T.H. Characterization of three types of beta zero-thalassemia resulting from a partial deletion of the beta-globin gene. Hemoglobin 13 (1989) 377-392
103. Padanilam B.J., Felice A.E., and Huisman T.H.J. Partial deletion of the 5′ β-globin gene region causes β-thalassemia in members of an American black family. Blood 64 (1984) 941-944
104. Popovich B.W., Rosenblatt D.S., Kendall A.G., and Nishioka Y. Molecular characterization of an atypical β-thalassemia caused by a large deletion in the 5′ β-globin gene region. Am. J. Hum. Genet. 39 (1986) 797-810
105. 2 beta 0-thalassemia due to a 532-basepair deletion of the 5′ beta-globin gene region. Blood 77 (1991) 1100-1103
106. 2 beta-thalassemia. J. Lab. Clin. Med. 118 (1991) 382
107. Wood W.G. Hereditary persistence of fetal hemoglobin and delta beta thalassemia. In: Steiberg M.H., Forget B.G., and Higg D.R. (Eds). Disorders of hemoglobin: genetics, pathophysiology and clinical management (2001), Cambridge University Press, Cambridge, UK 356-388
108. Forget B.G. Molecular basis of hereditary persistence of fetal hemoglobin. Ann. N. Y. Acad. Sci. 850 (1998) 38-44
109. Bollekens J.A., and Forget B.G. Delta beta thalassemia and hereditary persistence of fetal hemoglobin. Hematol. Oncol. Clin. North Am. 5 (1991) 399-422
110. Craig J.E., Rochette J., Sampietro M., et al. Genetic heterogeneity in heterocellular hereditary persistence of fetal hemoglobin. Blood 90 (1997) 428-434
111. Eivazi-Ziaei J., Dastgiri S., Pourebrahim S., and Soltanpour R. Usefulness of red blood cell flags in diagnosing and differentiating thalassemia trait from iron-deficiency anemia. Hematology 13 (2008) 253-256
112. Demir A., Yarali N., Fisgin T., Duru F., and Kara A. Most reliable indices in differentiation between thalassemia trait and iron deficiency anemia. Pediatr. Int. 44 (2002) 612-616
113. Okan V., Cigiloglu A., Cifci S., Yilmaz M., and Pehlivan M. Red cell indices and functions differentiating patients with the beta-thalassaemia trait from those with iron deficiency anaemia. J. Int. Med. Res. 37 (2009) 25-30
114. Cesana B.M., Maiolo A.T., Gidiuli R., Damilano I., Massaro P., and Polli E.E. Relevance of red cell distribution width (RDW) in the differential diagnosis of microcytic anaemias. Clin. Lab. Haematol. 13 (1991) 141-151
115. Aulakh R., Sohi I., Singh T., and Kakkar N. Red cell distribution width (RDW) in the diagnosis of iron deficiency with microcytic hypochromic anemia. Indian J. Pediatr. 76 (2009) 265-268
116. 2 levels in beta-thalassaemia trait with coincident iron deficiency. Indian J. Pathol. Microbiol. 41 (1998) 309-313
117. El-Agouza I., Abu Shahla A., and Sirdah M. The effect of iron deficiency anaemia on the levels of haemoglobin subtypes: possible consequences for clinical diagnosis. Clin. Lab. Haematol. 24 (2002) 285-289
118. 2 and E. J. Lab. Clin. Med. 71 (1968) 85-91
119. 2 levels: possible consequences for beta-thalassaemia screening. Scand. J. Clin. Lab. Invest. 59 (1999) 65-70
120. Henthorn P.S., Smithies O., and Mager D.L. Molecular analysis of deletions in the human beta-globin gene cluster: deletion junctions and locations of breakpoints. Genomics 6 (1990) 226-237
121. Craig J.E., Barnetson R., Weatherall D.J., and Thein S.L. Rapid detection of a 13.4-kb deletion causing delta beta thalassemia in an Egyptian family by polymerase chain reaction. Blood 8 (1993) 861-863
122. Bernini L.F., and Harteveld C.L. Alpha-thalassaemia. Baillieres Clin. Haematol. 11 (1998) 53-90
123. Oron-Karni V., Filon D., Shifrin Y., et al. Diversity of alpha-globin mutations and clinical presentation of alpha-thalassemia in Israel. Am. J. Hematol. 65 (2000) 196-203
124. Galanello R., Sollaino C., Paglietti E., et al. Alpha-thalassemia carrier identification by DNA analysis in the screening for thalassemia. Am. J. Hematol. 59 (1998) 273-278
125. Bouva M.J., Harteveld C.L., van Delft P., and Giordano P.C. Known and new delta globin gene mutations and their diagnostic significance. Haematologica 91 (2006) 129-132
126. Morgado A., Picanço I., Gomes S., et al. Mutational spectrum of delta-globin gene in the Portuguese population. Eur. J. Haematol. 79 (2007) 422-428
127. Giambona A., Passarello C., Ruggeri G., et al. Analysis of delta-globin gene alleles in the Sicilian population: identification of five new mutations. Haematologica 91 (2006) 1681-1684
128. 2 levels in Greek Cypriots. J. Biol. Chem. 271 (1996) 26931-26938
129. 2 values in an Italian population with a high prevalence of beta-thalassemia. Haematol 93 (2008) 1380-1384
130. Tamagnini G.P., Gonçalves P., Ribeiro M.L., et al. Beta-thalassemia mutations in the Portuguese; high frequencies of two alleles in restricted populations. Hemoglobin 17 (1993) 31-40
131. Efremov D.G., Dimovski A.J., Baysal E., et al. Possible factors influencing the haemoglobin and fetal haemoglobin levels in patients with beta-thalassaemia due to a homozygosity for the IVS-I-6 (T-->C) mutation. Br. J. Haematol. 86 4 (1994) 824-830
132. Trecartin R.F., Liebhaber S.A., Chang J.C., et al. Beta zero thalassemia in Sardinia is caused by a nonsense mutation. J. Clin. Invest. 68 (1981) 1012-1017
133. Spritz R.A., Jagadeeswaran P., Choudary P.V., et al. Base substitution in an intervening sequence of a beta+ thalassemic human globin gene. Proc. Natl. Acad. Sci. U. S. A. 78 (1981) 2455-2459
134. Orkin S.H., Kazazian Jr. H.H., Antonarakis S.E., et al. Linkage of beta-thalassaemia mutations and beta-globin gene polymorphisms with DNA polymorphisms in human beta-globin gene cluster. Nature 296 (1982) 627-631
135. Maragoudaki K.E., Kanavakis E., Traeger-Synodinos J., et al. Molecular, haematological and clinical studies of the - 101 C→T substitution of the beta globin gene promoter in 25 beta-thalassemia intermedia patients and 45 heterozygotes. Am. J. Hematol 107 (1999) 699-706
136. Divoky V., Baysal E., Schiliro G., Di Benedetto S.P., and Huisman T.H.A. mild type of Hb S-beta(+)-thalassemia [- 92(C-->T)] in a Sicilian family. Am. J. Hematol 2 (1993) 225-226
137. Goosens M., Dozy A.M., Embury S.H., et al. Triplicated α-globin loci in humans. Proc. Natl. Acad. Sci. U. S. A. 77 (1980) 518-521
138. 2 levels: implication for β-thalassemia carrier screening. Am. J. Hematol. 46 (1994) 79-81
139. GBianco I. Le Talassemie, un problema medico-sociale: ieri ed oggi. Collana studi e ricerche (1998), Istituto Italiano di Medicina Sociale, Editore Roma
140. Kutlar F., Felice A.E., Grech J.L., et al. The linkage of Hb Valletta [alpha 2 beta 287(f3)Thr----Pro] and Hb F-Malta-I [alpha 2G gamma 2117(G19)His----Arg] in the Maltese population. Hum. Genet. 86 (1991) 591-594
141. Rahbar S., Asmerom Y., and Blume K.G. A silent hemoglobin variant detected by HPLC: hemoglobin City of Hope beta 69 (E13) Gly>Ser. Hemoglobin 8 (1984) 333-342
142. Gallivan M. Personal communication 2005.
143. Giambona A., Vinciguerra M., Cassarà F., et al. Hb Marineo [beta70(E14)Ala>Val]: a silent hemoglobin variant with a mutation within the heme pocket. Hemoglobin 30 (2006) 139-148
144. Papassotiriou I., Traeger-Synodinos J., Promé D., et al. Association of unstable hemoglobin variants and heterozygous beta-thalassemia: example of a new variant Hb Acharnes or [beta53(D4) Ala > Thr]. Am. J. Hematol. 62 (1999) 186-192
145. Harteveld C.L., van Delft P., Plug R., et al. Hb Groene Hart. A new Pro>Ser amino acid substitution at position 119 of the alpha1-globin chain is associated with a mild alpha-thalassemia phenotype. Hemoglobin 26 (2002) 255-260
146. Groff P., Kalmes G., Golinska B., et al. Hb Ernz [beta123(H1)Thr>Asn] and Hb Renert [beta133(H11)Val>Ala]: two new neutral variants revealed by reversed phase high performance liquid chromatography analysis. Hemoglobin 24 (2000) 287-297
147. Blibech R., Mrad H., Kastally R., et al. Hemoglobin Beirut [alpha 2 beta 2(126)(H4)Val>Ala] in an Algerian family. Hemoglobin 10 (1986) 651-654
148. Bianco I., Cappabianca M.P., Foglietta E., et al. Silent thalassemias: genotypes and phenotypes. Haematologica 82 (1997) 257-258
149. Aguilar-Martinez P., Jourdan E., Brun S., et al. A novel mutation of the beta-globin gene promoter (- 102 C>A) and pitfalls in family screening. Am. J. Hematol. 82 (2007) 1088-1090
150. Moi P., Faà V., Marini M.G., et al. A novel silent beta-thalassemia mutation in the distal CACCC box affects the binding and responsiveness to EKLF. Br. J. Haematol. 126 (2004) 881-884
151. Wong C., Dowling C.E., Saiki R.K., Higuchi R.G., Erlich H.A., and Kazazian Jr. H.H. Characterization of beta-thalassaemia mutations using direct genomic sequencing of amplified single copy DNA. Nature 330 (1987) 384-386
152. Garewal G., Das R., Awasthi A., Ahluwalia J., and Marwaha R.K. The clinical significance of the spectrum of interactions of CAP+1 (A-->C), a silent beta-globin gene mutation, with other beta-thalassemia mutations and globin gene modifiers in north Indians. Eur. J. Haematol. 79 (2007) 417-421
153. Ho P.J., Rochette J., Fisher C.A., et al. Moderate reduction of beta-globin gene transcript by a novel mutation in the 5′ untranslated region: a study of its interaction with other genotypes in two families. Blood 871 (1996) 1170-1178
154. Bento M.C., Ribeiro M.L., Cunha E., Gonçalves P., Martin-Nuñez G., and Tamagnini G. β-thalassemia intermedia resulting from compound heterozygosity for an IVSI-1 (G-A) and a silent 5′ UTR + 33 (C-G) mutations. Haematologica 85 (2000) 443-444
155. Murru S., Loudianos G., Deiana M., et al. Molecular characterization of beta-thalassemia intermedia in patients of Italian descent and identification of three novel beta-thalassemia mutations. Blood 77 (1996) 1342-1347
156. Maragoudaki E., Vrettou C., Kanavakis E., Traeger-Synodinos J., Metaxotou-Mavrommati A., and Kattamis C. Molecular, haematological and clinical studies of a silent beta-gene C-->G mutation at 6 bp 3′ to the termination codon (+ 1480 C-->G) in twelve Greek families. Br. J. Haematol. 103 (1998) 45-51
157. 2 in hyperthyroidism. Hemoglobin 5 (1981) 571-577
158. 2 expression. J. Clin. Endocrinol. Metab. 57 (1983) 344-348
159. 2 au cours du pseudoxanthome elastique. Ann. Dermatol. Venereol. 133 (2006) 8-9
160. 2 values in an HIV-1-infected patient receiving antiretroviral drugs: a pitfall for thalassemia antenatal diagnosis. Hemoglobin 33 (2009) 158-161
161. 2 percentage in HIV infection: disease or treatment. AIDS 21 (2007) 1207-1220
162. 2 in nutritional megaloblastic anaemia. J. Med. Res. 77 (1983) 478-481
163. 2 measurement: data from an Italian pilot study with fresh whole blood samples and commercial HPLC systems. Clin. Chem. Lab. Med. 45 (2007) 88-92